<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02801409</url>
  </required_header>
  <id_info>
    <org_study_id>2013[653]</org_study_id>
    <secondary_id>ChiCTR-TRC-14004136</secondary_id>
    <nct_id>NCT02801409</nct_id>
  </id_info>
  <brief_title>Epidural Anesthesia-analgesia and Long-term Survival After Lung Cancer Surgery</brief_title>
  <official_title>Effects of Epidural Anesthesia-analgesia on Long-term Survival in Patients After Lung Cancer Surgery: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Available studies suggest that regional anesthesia-analgesia may decrease the occurrence of
      recurrence/metastasis in patients after cancer surgery. However, evidences from prospective
      studies are still lacking. The purpose of this randomized controlled trial is to investigate
      the effect of epidural anesthesia-analgesia on recurrence-free survival in patients
      undergoing lung cancer surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is increasing and is the leading cause of cancer death. Surgical resection is the
      mainstay of treatment for early stage non-small cell lung cancer. However, long-term survival
      after lung cancer surgery is far from optimal, and cancer recurrence or metastasis is the
      main reason leading to cancer death in these patients.

      The development of cancer recurrence/metastasis largely depends on the balance between
      tumor-promoting factors and immune function of the body. Studies showed that surgical
      manipulation releases cancer cells into circulation; and stress response induced by surgery
      inhibits the cell-mediated immunity. In addition, volatile anesthetics and opioids may also
      aggravate immunosuppression and potentially worsen long-term outcome. On the other hand,
      regional anesthesia can blunt surgical stress and reduce anesthetic consumption. These
      effects may help to preserve immune function and reduce recurrence/metastasis. However,
      existing evidences are insufficient to draw conclusion in this topic.

      The purpose of this randomized controlled trial is to test the hypothesize that regional
      anesthesia-analgesia may reduce recurrence/metastasis and improve long-term survival in
      patients after lung cancer surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2015</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 11, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival after surgery.</measure>
    <time_frame>Up to 4 years after surgery.</time_frame>
    <description>Time from surgery to the earliest date of recurrence/metastasis or death from any cause, whichever came first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of intensive care unit admission after surgery.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Rate of intensive care unit admission after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative complications during hospital stay.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Postoperative complications are defined as new-onset conditions that are harmful to patients' recovery and required therapeutic intervention, i.e., class II or higher on the Clavien-Dindo classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of chest tube placement.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Duration of chest tube placement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital after surgery.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Length of stay in hospital after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause mortality during hospital stay after surgery.</measure>
    <time_frame>Up to 30 days after surgery.</time_frame>
    <description>Rate of all-cause mortality during hospital stay after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate after surgery.</measure>
    <time_frame>Up to 4 year after surgery.</time_frame>
    <description>Time from surgery to all-cause death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific survival after surgery.</measure>
    <time_frame>Up to 4 years after surgery.</time_frame>
    <description>Time from surgery to cancer-specific death; deaths from other causes are censored at the time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity engagement in 1-year survivors.</measure>
    <time_frame>At the end of the first year after surgery.</time_frame>
    <description>Activity engagement is measured with metabolic equivalents. Activity of &gt;9 metabolic equivalents indicates full physical recovery.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain intensity after surgery.</measure>
    <time_frame>During the first 3 days after surgery.</time_frame>
    <description>Assessed with the numeric rating score, an 11-point scale where 0 = no pain and 10 = the most severe pain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Recurrence-free survival in cancer patients.</measure>
    <time_frame>Up to 4 years after surgery.</time_frame>
    <description>Time from surgery to the earliest date of recurrence/metastasis or death from any cause, whichever came first.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival in cancer patients.</measure>
    <time_frame>Up to 4 years after surgery.</time_frame>
    <description>Time from surgery to all-cause death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cancer-specific survival in cancer patients.</measure>
    <time_frame>Up to 4 years after surgery.</time_frame>
    <description>Time from surgery to cancer-specific death; deaths from other causes are censored at the time of death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of CD8+ and FOXP3+ T cells per mm2 tumor area (sub-study).</measure>
    <time_frame>After resection of lung adenocarcinoma specimens</time_frame>
    <description>Immunohistochemical staining of CD8 and FOXP3 molecules in excised lung adenocarcinoma specimens. Performed in part of enrolled patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of NK-cells and T-cell subgroups in peripheral blood (sub-study).</measure>
    <time_frame>Peripheral blood samples collected before induction, at the end of surgery and at 24 hours after surgery.</time_frame>
    <description>Measured by flow cytometry. Performed in part of enrolled patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of chronic pain at 3 month and 6 month after surgery (sub-study).</measure>
    <time_frame>At 3 months and 6 months after surgery.</time_frame>
    <description>Chronic pain is measured with the Brief Pain Inventory (BPI), neuropathic pain screening questionnaire (ID pain), and McGill Pain Questionnair (MPQ). Performed in part of enrolled patients.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Thoracic Surgery</condition>
  <condition>Anesthesia, Epidural</condition>
  <condition>Neoplasm Recurrence, Local</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>General anesthesia alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined epidural-general anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>General anesthesia alone</intervention_name>
    <description>General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.</description>
    <arm_group_label>General anesthesia alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined epidural-general anesthesia</intervention_name>
    <description>Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.</description>
    <arm_group_label>Combined epidural-general anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (aged 18-80 years);

          2. Clinically diagnosed as primary non-small cell lung cancer of stage IA to IIIA, and
             scheduled for radical surgery;

          3. Agreed to receive patient-controlled analgesia after surgery.

        Exclusion Criteria:

          1. Distant metastasis, malignant tumor in other organs, or chemo-/radiotherapy or other
             anti-cancer therapy before surgery;

          2. Comorbid with autoimmune diseases, or glucocorticoid/immunosuppressant therapy within
             1 year;

          3. History of schizophrenia, epilepsy or Parkinson disease, or unable to complete
             preoperative assessment due to severe dementia, language barrier, or end-stage
             disease;

          4. Severe hepatic disease (Child-Pugh classification C), renal failure (serum creatinine
             &gt;442 umol/L or receiving renal replacement therapy), or American Society of
             Anesthesiologists classification IV or higher;

          5. History of anesthesia and/or surgery within 1 year;

          6. Contraindications to epidural anesthesia, including spinal deformity, coagulation
             dysfunction, local infection, and history of spinal trauma/surgery;

          7. Allergic to any medications used during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Xin Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kelsey CR, Marks LB, Hollis D, Hubbs JL, Ready NE, D'Amico TA, Boyd JA. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 2009 Nov 15;115(22):5218-27. doi: 10.1002/cncr.24625.</citation>
    <PMID>19672942</PMID>
  </reference>
  <reference>
    <citation>Sawyer TE, Bonner JA, Gould PM, Foote RL, Deschamps C, Lange CM, Li H. Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma. Ann Thorac Surg. 1999 Oct;68(4):1171-6.</citation>
    <PMID>10543475</PMID>
  </reference>
  <reference>
    <citation>Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth. 2010 Aug;105(2):106-15. doi: 10.1093/bja/aeq164. Review.</citation>
    <PMID>20627881</PMID>
  </reference>
  <reference>
    <citation>Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007 Dec 6;450(7171):903-7. Epub 2007 Nov 18.</citation>
    <PMID>18026089</PMID>
  </reference>
  <reference>
    <citation>Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003 Oct;10(8):972-92. Review.</citation>
    <PMID>14527919</PMID>
  </reference>
  <reference>
    <citation>Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg. 2000 Jul;232(1):58-65.</citation>
    <PMID>10862196</PMID>
  </reference>
  <reference>
    <citation>Hofer SO, Molema G, Hermens RA, Wanebo HJ, Reichner JS, Hoekstra HJ. The effect of surgical wounding on tumour development. Eur J Surg Oncol. 1999 Jun;25(3):231-43. Review.</citation>
    <PMID>10336800</PMID>
  </reference>
  <reference>
    <citation>Lennard TW, Shenton BK, Borzotta A, Donnelly PK, White M, Gerrie LM, Proud G, Taylor RM. The influence of surgical operations on components of the human immune system. Br J Surg. 1985 Oct;72(10):771-6.</citation>
    <PMID>2412626</PMID>
  </reference>
  <reference>
    <citation>Carter JJ, Whelan RL. The immunologic consequences of laparoscopy in oncology. Surg Oncol Clin N Am. 2001 Jul;10(3):655-77. Review.</citation>
    <PMID>11685934</PMID>
  </reference>
  <reference>
    <citation>Tashiro T, Yamamori H, Takagi K, Hayashi N, Furukawa K, Nitta H, Toyoda Y, Sano W, Itabashi T, Nishiya K, Hirano J, Nakajima N. Changes in immune function following surgery for esophageal carcinoma. Nutrition. 1999 Oct;15(10):760-6.</citation>
    <PMID>10501289</PMID>
  </reference>
  <reference>
    <citation>Downing JE, Miyan JA. Neural immunoregulation: emerging roles for nerves in immune homeostasis and disease. Immunol Today. 2000 Jun;21(6):281-9. Review.</citation>
    <PMID>10825740</PMID>
  </reference>
  <reference>
    <citation>Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000 Dec;52(4):595-638. Review.</citation>
    <PMID>11121511</PMID>
  </reference>
  <reference>
    <citation>Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain. 2001 Feb 1;90(1-2):191-9.</citation>
    <PMID>11166986</PMID>
  </reference>
  <reference>
    <citation>Afsharimani B, Cabot PJ, Parat MO. Morphine use in cancer surgery. Front Pharmacol. 2011 Aug 8;2:46. doi: 10.3389/fphar.2011.00046. eCollection 2011.</citation>
    <PMID>21852973</PMID>
  </reference>
  <reference>
    <citation>Xu YX, Ayala A, Chaudry IH. Prolonged immunodepression after trauma and hemorrhagic shock. J Trauma. 1998 Feb;44(2):335-41.</citation>
    <PMID>9498507</PMID>
  </reference>
  <reference>
    <citation>Klein HG. Immunomodulatory aspects of transfusion: a once and future risk? Anesthesiology. 1999 Sep;91(3):861-5. Review.</citation>
    <PMID>10485799</PMID>
  </reference>
  <reference>
    <citation>Gottschalk A, Sharma S, Ford J, Durieux ME, Tiouririne M. Review article: the role of the perioperative period in recurrence after cancer surgery. Anesth Analg. 2010 Jun 1;110(6):1636-43. doi: 10.1213/ANE.0b013e3181de0ab6. Epub 2010 Apr 30.</citation>
    <PMID>20435944</PMID>
  </reference>
  <reference>
    <citation>Ishihara Y, Matsunaga K, Iijima H, Fujii T, Oguchi Y, Kagawa J. Time-dependent effects of stressor application on metastasis of tumor cells in the lung and its regulation by an immunomodulator in mice. Psychoneuroendocrinology. 1999 Oct;24(7):713-26.</citation>
    <PMID>10451907</PMID>
  </reference>
  <reference>
    <citation>Freire-Garabal M, Núñez MJ, Balboa JL, Fernández-Rial JC, Vallejo LG, González-Bahillo J, Rey-Méndez M. Effects of alprazolam on cellular immune response to surgical stress in mice. Cancer Lett. 1993 Sep 30;73(2-3):155-60.</citation>
    <PMID>8221628</PMID>
  </reference>
  <reference>
    <citation>Andersen BL, Farrar WB, Golden-Kreutz D, Kutz LA, MacCallum R, Courtney ME, Glaser R. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst. 1998 Jan 7;90(1):30-6.</citation>
    <PMID>9428780</PMID>
  </reference>
  <reference>
    <citation>Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth. 2012 Dec;109 Suppl 1:i17-i28. doi: 10.1093/bja/aes421. Review.</citation>
    <PMID>23242747</PMID>
  </reference>
  <reference>
    <citation>Conrick-Martin I, Buggy DJ. The effects of anesthetic and analgesic techniques on immune function. J Clin Anesth. 2013 Jun;25(4):253-4. doi: 10.1016/j.jclinane.2013.04.003. Epub 2013 Apr 26.</citation>
    <PMID>23624071</PMID>
  </reference>
  <reference>
    <citation>Ahlers O, Nachtigall I, Lenze J, Goldmann A, Schulte E, Höhne C, Fritz G, Keh D. Intraoperative thoracic epidural anaesthesia attenuates stress-induced immunosuppression in patients undergoing major abdominal surgery. Br J Anaesth. 2008 Dec;101(6):781-7. doi: 10.1093/bja/aen287. Epub 2008 Oct 15.</citation>
    <PMID>18922851</PMID>
  </reference>
  <reference>
    <citation>Piegeler T, Votta-Velis EG, Liu G, Place AT, Schwartz DE, Beck-Schimmer B, Minshall RD, Borgeat A. Antimetastatic potential of amide-linked local anesthetics: inhibition of lung adenocarcinoma cell migration and inflammatory Src signaling independent of sodium channel blockade. Anesthesiology. 2012 Sep;117(3):548-59.</citation>
    <PMID>22846676</PMID>
  </reference>
  <reference>
    <citation>Waurick R, Van Aken H. Update in thoracic epidural anaesthesia. Best Pract Res Clin Anaesthesiol. 2005 Jun;19(2):201-13. Review.</citation>
    <PMID>15966493</PMID>
  </reference>
  <reference>
    <citation>Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. 2008 Aug;109(2):180-7. doi: 10.1097/ALN.0b013e31817f5b73.</citation>
    <PMID>18648226</PMID>
  </reference>
  <reference>
    <citation>Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006 Oct;105(4):660-4.</citation>
    <PMID>17006061</PMID>
  </reference>
  <reference>
    <citation>Tsui BC, Rashiq S, Schopflocher D, Murtha A, Broemling S, Pillay J, Finucane BT. Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Can J Anaesth. 2010 Feb;57(2):107-12. doi: 10.1007/s12630-009-9214-7.</citation>
    <PMID>19911247</PMID>
  </reference>
  <reference>
    <citation>Lin L, Liu C, Tan H, Ouyang H, Zhang Y, Zeng W. Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br J Anaesth. 2011 Jun;106(6):814-22. doi: 10.1093/bja/aer055. Epub 2011 Mar 24.</citation>
    <PMID>21436156</PMID>
  </reference>
  <reference>
    <citation>Cummings KC 3rd, Xu F, Cummings LC, Cooper GS. A comparison of epidural analgesia and traditional pain management effects on survival and cancer recurrence after colectomy: a population-based study. Anesthesiology. 2012 Apr;116(4):797-806. doi: 10.1097/ALN.0b013e31824674f6.</citation>
    <PMID>22273991</PMID>
  </reference>
  <reference>
    <citation>Ismail H, Ho KM, Narayan K, Kondalsamy-Chennakesavan S. Effect of neuraxial anaesthesia on tumour progression in cervical cancer patients treated with brachytherapy: a retrospective cohort study. Br J Anaesth. 2010 Aug;105(2):145-9. doi: 10.1093/bja/aeq156. Epub 2010 Jun 23.</citation>
    <PMID>20573631</PMID>
  </reference>
  <reference>
    <citation>Lai R, Peng Z, Chen D, Wang X, Xing W, Zeng W, Chen M. The effects of anesthetic technique on cancer recurrence in percutaneous radiofrequency ablation of small hepatocellular carcinoma. Anesth Analg. 2012 Feb;114(2):290-6. doi: 10.1213/ANE.0b013e318239c2e3. Epub 2011 Nov 21. Erratum in: Anesth Analg. 2013 Jan;116(1):266.</citation>
    <PMID>22104077</PMID>
  </reference>
  <reference>
    <citation>Gupta A, Björnsson A, Fredriksson M, Hallböök O, Eintrei C. Reduction in mortality after epidural anaesthesia and analgesia in patients undergoing rectal but not colonic cancer surgery: a retrospective analysis of data from 655 patients in central Sweden. Br J Anaesth. 2011 Aug;107(2):164-70. doi: 10.1093/bja/aer100. Epub 2011 May 17.</citation>
    <PMID>21586443</PMID>
  </reference>
  <reference>
    <citation>Christopherson R, James KE, Tableman M, Marshall P, Johnson FE. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg. 2008 Jul;107(1):325-32. doi: 10.1213/ane.0b013e3181770f55.</citation>
    <PMID>18635504</PMID>
  </reference>
  <reference>
    <citation>Gottschalk A, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, Durieux ME, Nemergut EC. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology. 2010 Jul;113(1):27-34. doi: 10.1097/ALN.0b013e3181de6d0d.</citation>
    <PMID>20508494</PMID>
  </reference>
  <reference>
    <citation>Wuethrich PY, Hsu Schmitz SF, Kessler TM, Thalmann GN, Studer UE, Stueber F, Burkhard FC. Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: a retrospective study. Anesthesiology. 2010 Sep;113(3):570-6. doi: 10.1097/ALN.0b013e3181e4f6ec.</citation>
    <PMID>20683253</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, Sessler DI; ANZCA Trials Group Investigators. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ. 2011 Mar 29;342:d1491. doi: 10.1136/bmj.d1491.</citation>
    <PMID>21447587</PMID>
  </reference>
  <reference>
    <citation>Taylor MD, Nagji AS, Bhamidipati CM, Theodosakis N, Kozower BD, Lau CL, Jones DR. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012 Jun;93(6):1813-20; discussion 1820-1. doi: 10.1016/j.athoracsur.2012.03.031. Epub 2012 Apr 26.</citation>
    <PMID>22542070</PMID>
  </reference>
  <reference>
    <citation>Alberts WM. Follow up and surveillance of the patient with lung cancer: what do you do after surgery? Respirology. 2007 Jan;12(1):16-21. Review.</citation>
    <PMID>17207020</PMID>
  </reference>
  <reference>
    <citation>Colt HG, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e437S-e454S. doi: 10.1378/chest.12-2365.</citation>
    <PMID>23649451</PMID>
  </reference>
  <reference>
    <citation>Bruzzi JF, Munden RF. PET/CT imaging of lung cancer. J Thorac Imaging. 2006 May;21(2):123-36. Review.</citation>
    <PMID>16770229</PMID>
  </reference>
  <reference>
    <citation>Pei L, Tan G, Wang L, Guo W, Xiao B, Gao X, Wang L, Li H, Xu Z, Zhang X, Zhao J, Yi J, Huang Y. Comparison of combined general-epidural anesthesia with general anesthesia effects on survival and cancer recurrence: a meta-analysis of retrospective and prospective studies. PLoS One. 2014 Dec 30;9(12):e114667. doi: 10.1371/journal.pone.0114667. eCollection 2014.</citation>
    <PMID>25548913</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 12, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Xin Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Surgical Resection</keyword>
  <keyword>Epidural Anesthesia and Analgesia</keyword>
  <keyword>Cancer recurrence/metastasis</keyword>
  <keyword>Long-Term Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasm Recurrence, Local</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

